Upstream Bio (NASDAQ:UPB) Now Covered by Piper Sandler

Piper Sandler assumed coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note published on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $75.00 price target on the stock.

A number of other equities analysts have also commented on UPB. TD Cowen assumed coverage on Upstream Bio in a research note on Tuesday. They issued a “buy” rating on the stock. JPMorgan Chase & Co. began coverage on Upstream Bio in a report on Tuesday. They issued an “overweight” rating and a $38.00 target price for the company. Finally, William Blair began coverage on Upstream Bio in a report on Tuesday. They issued an “outperform” rating for the company.

Upstream Bio Stock Up 8.9 %

Upstream Bio stock opened at $27.39 on Tuesday. Upstream Bio has a one year low of $20.74 and a one year high of $28.98.

Insiders Place Their Bets

In other Upstream Bio news, Director Erez Chimovits bought 825,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares in the company, valued at $77,432,841. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Erez Chimovits acquired 825,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the acquisition, the director now directly owns 4,554,873 shares in the company, valued at $77,432,841. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the acquisition, the insider now owns 1,175,000 shares of the company’s stock, valued at approximately $19,975,000. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.